List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Overview
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development
ADM Therapeutics
Boehringer Ingelheim International GmbH
Eli Lilly and Co
Neurimmune Holding AG
Nordic Bioscience AS
reMYND NV
Zealand Pharma AS
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles
AC-253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADM-116 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DACRA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-056 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ReS-39 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Obesity and Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit ABPP and IAPP for Alzheimer's Disease and Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Target IAPP for Obesity and Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-4982 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-5461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Products
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Product Development Milestones
Featured News & Press Releases
Appendix

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by ADM Therapeutics, H1 2020
Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Neurimmune Holding AG, H1 2020
Pipeline by Nordic Bioscience AS, H1 2020
Pipeline by reMYND NV, H1 2020
Pipeline by Zealand Pharma AS, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List of Figures
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Companies Mentioned
• ADM Therapeutics
• Boehringer Ingelheim International GmbH
• Eli Lilly and Co
• Neurimmune Holding AG
• Nordic Bioscience AS
• reMYND NV
• Zealand Pharma AS